KLACID LA Irlandia - angielski - HPRA (Health Products Regulatory Authority)

klacid la

clear pharmacy - clarithromycin - modified-release tablets - 500 milligram

KLACID MR TABLET 500 mg Singapur - angielski - HSA (Health Sciences Authority)

klacid mr tablet 500 mg

abbott laboratories (singapore ) private limited - clarithromycin - tablet, extended release - 500 mg - clarithromycin 500 mg

KLACID XL 500 mg Modified-Release Tablet Kenia - angielski - Pharmacy and Poisons Board

klacid xl 500 mg modified-release tablet

abbott laboratories s.a. (pty) ltd 219 golf club terrace constantia kloof 1709 - clarithromycin - modified-release tablet - 500 mg - antibacterials for systemic use: macrolides

KLACID LA Irlandia - angielski - HPRA (Health Products Regulatory Authority)

klacid la

imed healthcare ltd. - clarithromycin - modified-release tablets - 500 milligram

Klacid 250mg Film-Coated Tablets Malta - angielski - Medicines Authority

klacid 250mg film-coated tablets

abbott laboratories limited - clarithromycin 250 mg - film-coated tablet

Klacid 500mg Film-Coated Tablets Malta - angielski - Medicines Authority

klacid 500mg film-coated tablets

abbott laboratories limited - clarithromycin 500 mg - film-coated tablet

Klacid 250 mg film-coated tablets Irlandia - angielski - HPRA (Health Products Regulatory Authority)

klacid 250 mg film-coated tablets

mylan ire healthcare limited - clarithromycin - film-coated tablet - 250 milligram(s) - macrolides; clarithromycin - antibacterial for systemic use, macrolide - it is indicated for the treatment of infections due to susceptible organisms. such infections include: 1. lower respiratory tract infections (e.g. bronchitis, pneumonia). 2. upper respiratory tract infections (e.g. pharyngitis, sinusitis). 3. skin and soft tissue infections (e.g. folliculitis, cellulitis, erysipelas). 4. disseminated or localised mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare. localised infections due to mycobacterium chelonae, mycobacterium fortuitum or mycobacterium kansasii. 5. clarithromycin is indicated for the prevention of disseminated mycobacterium avium complex infection in hivinfected patients with cd4 lymphocyte counts less than or equal to 100/mm3. 6. clarithromycin in the presence of acid suppression is indicated for the eradication of h. pylori, resulting in decreased recurrence of duodenal ulcer. (see further information).

Klacid XL Namibia - angielski - Namibia Medicines Regulatory Council

klacid xl

abbott laboratories sa (pty) ltd - clirthromycin - tablets - clirthromycin 500mg modified release tablets

Klacid 250 mg film-coated tablets Irlandia - angielski - HPRA (Health Products Regulatory Authority)

klacid 250 mg film-coated tablets

viatris healthcare limited - clarithromycin - film-coated tablet - macrolides; clarithromycin

KLACID FORTE TABLET 500 mg Singapur - angielski - HSA (Health Sciences Authority)

klacid forte tablet 500 mg

abbott laboratories (singapore ) private limited - clarithromycin - tablet, film coated - 500 mg - clarithromycin 500 mg